320 related articles for article (PubMed ID: 20181452)
1. [Use of sorafenib in patients with hepatocellular or renal carcinoma].
Rosmorduc O; Chevreau C; Dielenseger P; Ederhy S; Goldwasser F; Grange JD; Mortier L; Neidhardt-Berard ME; Robert C; Scotté F; Seitz JF
Gastroenterol Clin Biol; 2010 Mar; 34(3):161-7. PubMed ID: 20181452
[TBL] [Abstract][Full Text] [Related]
2. Strategies for assessing and managing the adverse events of sorafenib and other targeted therapies in the treatment of renal cell and hepatocellular carcinoma: recommendations from a European nursing task group.
Edmonds K; Hull D; Spencer-Shaw A; Koldenhof J; Chrysou M; Boers-Doets C; Molassiotis A
Eur J Oncol Nurs; 2012 Apr; 16(2):172-84. PubMed ID: 21641280
[TBL] [Abstract][Full Text] [Related]
3. Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib.
Lacouture ME; Reilly LM; Gerami P; Guitart J
Ann Oncol; 2008 Nov; 19(11):1955-61. PubMed ID: 18550575
[TBL] [Abstract][Full Text] [Related]
4. [Clinical observation of sorafenib monotherapy in Chinese patients with advanced hepatocellular carcinoma].
Xu L; Li P; Lin XJ; Yuan YF; Zhang YQ; Chen MS
Zhonghua Zhong Liu Za Zhi; 2009 Jan; 31(1):58-61. PubMed ID: 19538872
[TBL] [Abstract][Full Text] [Related]
5. The effect of sorafenib treatment on the diabetic status of patients with renal cell or hepatocellular carcinoma.
Imarisio I; Paglino C; Ganini C; Magnani L; Caccialanza R; Porta C
Future Oncol; 2012 Aug; 8(8):1051-7. PubMed ID: 22894676
[TBL] [Abstract][Full Text] [Related]
6. Sorafenib-induced hand-foot skin reaction: a Koebner phenomenon?
Sibaud V; Delord JP; Chevreau C
Target Oncol; 2009 Dec; 4(4):307-10. PubMed ID: 19894099
[TBL] [Abstract][Full Text] [Related]
7. [Sorafenib(Nexavar)].
Miyanaga N; Akaza H
Gan To Kagaku Ryoho; 2009 Jun; 36(6):1029-33. PubMed ID: 19542731
[TBL] [Abstract][Full Text] [Related]
8. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.
Lee WJ; Lee JL; Chang SE; Lee MW; Kang YK; Choi JH; Moon KC; Koh JK
Br J Dermatol; 2009 Nov; 161(5):1045-51. PubMed ID: 19558553
[TBL] [Abstract][Full Text] [Related]
9. [The outcome of chemotherapy by sorafenib in advanced hepatocellular carcinoma].
Amano R; Yamada N; Noda E; Kubo N; Tanaka H; Muguruma K; Takashima T; Yashiro M; Maeda K; Onoda N; Sawada T; Nakata B; Ohira M; Ishikawa T; Hirakawa K
Gan To Kagaku Ryoho; 2010 Nov; 37(12):2676-8. PubMed ID: 21224677
[TBL] [Abstract][Full Text] [Related]
10. Sorafenib.
Rini BI
Expert Opin Pharmacother; 2006 Mar; 7(4):453-61. PubMed ID: 16503817
[TBL] [Abstract][Full Text] [Related]
11. Speeding up cancer-drug development.
Burton A
Lancet Oncol; 2006 Oct; 7(10):798. PubMed ID: 17039633
[No Abstract] [Full Text] [Related]
12. Sorafenib and sunitinib: novel targeted therapies for renal cell cancer.
Grandinetti CA; Goldspiel BR
Pharmacotherapy; 2007 Aug; 27(8):1125-44. PubMed ID: 17655513
[TBL] [Abstract][Full Text] [Related]
13. Sorafenib.
Hasskarl J
Recent Results Cancer Res; 2010; 184():61-70. PubMed ID: 20072831
[TBL] [Abstract][Full Text] [Related]
14. [Hand-foot syndrome and sorafenib].
Milano G; Mortier L; Digue L; Desmedt E; Ravaud A
Bull Cancer; 2009 Feb; 96(2):191-7. PubMed ID: 19258226
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib [corrected] in kidney cancer.
Escudier B
Ann Oncol; 2007 Jul; 18 Suppl 9():ix90-3. PubMed ID: 17631603
[No Abstract] [Full Text] [Related]
16. Sorafenib in hepatocellular carcinoma.
Josephs DH; Ross PJ
Br J Hosp Med (Lond); 2010 Aug; 71(8):451-6. PubMed ID: 20852487
[TBL] [Abstract][Full Text] [Related]
17. Target therapy for hepatocellular carcinoma: is sorafenib for everybody?
Daniele B; Di Maio M
J Clin Gastroenterol; 2009; 43(5):389-90. PubMed ID: 19564813
[No Abstract] [Full Text] [Related]
18. [Hepatocellular carcinoma - long-term treatable disease].
Fínek J
Klin Onkol; 2012; 25(4):287-9. PubMed ID: 22920170
[TBL] [Abstract][Full Text] [Related]
19. Sorafenib in advanced hepatocellular carcinoma.
Spinzi G; Paggi S
N Engl J Med; 2008 Dec; 359(23):2497-8; author reply 2498-9. PubMed ID: 19052134
[No Abstract] [Full Text] [Related]
20. Severe sorafenib-induced hand-foot skin reaction.
Cuesta L; Betlloch I; Toledo F; Latorre N; Monteagudo A
Dermatol Online J; 2011 May; 17(5):14. PubMed ID: 21635836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]